GlaxoSmithKline‘s (NYSE:GSK) interest in tiny neural implants is stronger than ever, even amid declining earnings and flopped drug candidates that have turned CEO Andrew Witty into a lame duck who will step aside in 2017. Despite the turmoil, the British pharma giant is investing $50 million in so-called bioelectronics via Action Potential Ventures, aiming to fund companies […]
Fresenius, Smiths in the hunt for Pfizer’s $1.5B infusion pump biz
Germany’s Fresenius (NYSE:FMS) and Britain’s Smiths Group (LON:SMIN) have emerged as the final bidders for Pfizer‘s (NYSE:PFE) infusion pump business, inherited via the Big Pharma’s September 2015 purchase of Hospira for $15 billion. The winning bid is expected to be around $1.5 billion, according to Reuters. Private equity firm Pamplona Capital Management was also interested and reportedly made a […]
Otsuka gets in on ReCor Medical's Paradise renal denervation device
ReCor Medical said it landed a strategic investment from Japanese conglomerate Otsuka Pharmaceutical (TYO:4578) that will bring to Asia its Paradise renal denervation device for treating hypertension. Neither side is disclosing financial terms, but the deal calls for Otsuka to receive exclusive rights to pursue clinical trials, regulatory approval and commercialization of ReCor’s Paradise device in Japan, China, Korea […]
FDA OKs Endo's opioid cheek patch licensed from BioDelivery Sciences
(Reuters) — BioDelivery Sciences International said the FDA approved its opioid cheek patch for chronic pain, sending the drugmaker’s shares up 23% in premarket trading today. Endo International (NSDQ:ENDP) licensed the worldwide manufacturing and marketing rights to the treatment, Belbuca, from BioDelivery in 2012. Belbuca is an opioid film patch and aims to treat patients with […]
FDA rejects AcelRx's request for meeting on pain drug device
FDA seeks additional trial on Zalviso drug-device combo from AcelRx
(Reuters) — AcelRx Pharmaceuticals (NSDQ:ACRX) said the FDA wants an additional study on its Zalviso drug-device combination, which the safety watchdog already rejected once last year.
Unilife signs production deal with Flextronics
Intersect ENT registers $80M IPO for sinus implants

Drug-eluting devices maker Intersect ENT hopes to raise as much as $80 million in a newly registered initial public offering, according to SEC documents filed this week.
Delcath Systems tanks following reverse stock split
Corium poised for $66M IPO for wearable drug-delivery devices

Drug-delivery devices maker Corium could raise up to $66 million through an initial public offering, the company announced in SEC filings today.
Corium plans to offer 5.5 million shares of common stock for $10-$12 apiece, putting its total offering value at between $55-$66 million. At the middle rate of $11 per share, Corium expects its net proceeds to amount to $53.7 million after expenses.